BETAHISTINE 8mg. IP

An antivertigo drug that is employed in the management of vertigo and vestibular pathologies of different aetiologies. (Lacour, 2013) Exerts a positive effect in terms of reduction in vertigo symptoms. (Louisa Murdin K. H., 2016) An effective therapy for Meniere’s disease and related conditions. (Van Esch B, 2020) Improves the symptoms related to Meniere’s disease, such as vertigo sensation. Effectively reduces the pressure and ameliorates the blood flow to certain areas within the inner ear. (Deborah A Hall, 2018) Reduces the frequency and severity of vertiginous episodes, hearing loss, tinnitus. (Cochrane ENT Group, 2001) Arrests the progression of hearing loss in patients with Meniere’s syndrome. (Cochrane ENT Group, 2001) Demonstrates the maximum benefit in different types of peripheral vertigo, especially in Meniere's disease. (M V Zamergrad, 2021) A useful therapeutic medicament for the treatment of dizziness and vertigo during the intercritical phase of the disease. (A.P. Casani, 2018) An effective and safe option for the treatment of peripheral vertigo. (Rubén Ramos Alcocer, 2015) Decreases the frequency of vertigo attacks from 6.7 per month to 2.06 per month in Meniere’s disease. (Michel Lacour, 2007)